YOLFTbeta
09

Genexine Inc

095700 · KQ · Healthcare / Biotechnology

1,963.00KRW-77.00 (-3.77%)

Price History

Full chart

Market Stats

Previous Close2,040.00
Open2,040.00
Day Range1,961.00 – 2,060.00
52-Week Range2,140.00 – 7,490.00
Volume169.50K
Market Cap127.34B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.41
50-Day Avg2,751.70
200-Day Avg3,909.70

About

Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses in the human body to fight viral infection and cancer cells. Its product pipeline includes GX-H9, which is in Phase II and III clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E4 that is in Phase III clinical trials for the treatment of anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; GX-I7, a product candidate in Phase I and II clinical trials to treat solid tumors, lymphopenia, and COVID-19; GX-P1, which is in Phase I clinical trials for the treatment of autoimmune diseases and transplantation; and GX-G6 that is in Phase II clinical trials for the treatment of diabetes. The company is also developing GX-188E that is in Phase II clinical trials for the treatment of cervical cancer, and head and neck cancer. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Jungwon Woo Ph.D.
  • Employees86
  • HeadquartersBio Innovation Park, Seoul, South Korea, 07789, Korea
  • Websitehttps://www.genexine.com

Leadership

  • Dr. Jungwon Woo Ph.D.President & Director
  • Mr. Neil K. Warma M.B.A.President & Director · b. 1963
  • Dr. Young-Chul Sung Ph.D.Founder & Chairman of the Scientific Advisory Board · b. 1956
  • Mr. Seong-Jun Hong CPAExecutive VP, CFO & Director · b. 1965
  • Jongsoo LeeSenior Manager of IR & PR
  • Hyun Jin ParkEVP of Corporate Development
  • Dr. Jong Sup Park M.D., Ph.D.Chief Medical Officer
  • Jang Hee LeeEVP of Operations
  • Ki Yong KimSVP of Bio Research Institute
  • Chul Jun HyunAuditor & Director

Financials

Income Statement

Currency: KRW2009-12-312010-12-312011-12-312012-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.07B1.08B2.66B6.25B32.52B11.35B28.45B12.88B11.30B18.54B36.83B16.14B4.43B2.93B4.57B
Growth (%)-+0.94%+146.58%+134.91%+420.18%-65.09%+150.66%-54.73%-12.25%+64.06%+98.61%-56.18%-72.57%-33.75%+55.96%
Cost of Revenue151.45M277.98M358.09M901.62M4.90B4.78B10.69B6.33B3.85B6.87B5.02B4.78B4.04B4.17B4.96B
Gross Profit917.80M801.32M2.30B5.35B27.62B6.57B17.76B6.55B7.45B11.68B31.81B11.36B387.49M-1.24B-385.72M
Gross Margin85.84%74.24%86.54%85.58%84.94%57.91%62.42%50.88%65.94%62.97%86.36%70.41%8.75%-42.31%-8.43%
Operating Expense1.39B7.87B8.89B8.03B27.72B37.49B44.65B44.71B51.99B58.27B52.00B45.83B42.78B35.70B35.69B
Operating Income-474.24M-7.07B-6.59B-2.68B-94.75M-30.91B-26.89B-38.15B-44.54B-46.59B-20.19B-34.47B-42.40B-36.94B-36.07B
Operating Margin-44.35%-655.35%-247.67%-42.93%-0.29%-272.30%-94.50%-296.18%-394.06%-251.25%-54.83%-213.55%-957.76%-1259.69%-788.67%
EBITDA------------48.15B-57.72B-57.33B-17.74B
EBITDA Margin------------298.34%-1303.88%-1954.92%-387.81%
Net Income-493.57M-4.71B-7.05B-2.10B-1.43B-30.93B-19.33B-34.07B-16.51B27.57B-47.73B-56.27B-66.87B-63.71B-27.22B
Net Income Margin-46.16%-436.26%-265.05%-33.53%-4.39%-272.49%-67.93%-264.46%-146.06%148.68%-129.59%-348.69%-1510.71%-2172.23%-595.01%
R&D5.56B5.56B4.05B283.31M-----39.21B33.12B26.44B26.33B22.02B26.62B
R&D as % of Total Revenue519.87%515.03%152.20%4.53%-----211.43%89.92%163.86%594.82%750.96%581.92%
Interest Expense0000000002.92B492.37M3.31B4.11B2.65B2.44B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%15.76%1.34%20.48%92.87%90.19%53.42%

Balance Sheet

Currency: KRW2009-12-312010-12-312011-12-312012-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets42.78B37.67B39.19B63.38B142.10B198.71B140.73B374.81B358.18B596.91B636.86B388.78B376.59B345.04B371.27B
Total Liabilities4.28B11.24B15.14B17.55B16.33B28.47B26.83B54.30B61.27B61.30B119.12B112.63B79.68B83.36B124.51B
Total Equity38.47B26.43B24.20B45.83B125.77B170.24B113.91B320.51B296.91B535.60B517.74B276.15B296.62B261.68B246.76B
Cash1.76B3.17B3.98B4.46B-2.62B24.46B11.79B57.03B19.05B5.21B27.80B17.94B6.03B1.16B9.15B
Total Debt------14.46B34.61B29.21B25.96B-----
Net Debt---------21.58B24.05B65.79B61.22B74.47B98.64B

Cash Flow

Currency: KRW2009-12-312010-12-312011-12-312012-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow35.23M-4.62B-3.48B1.67B-1.64B-14.10B-26.10B-20.05B-41.57B-22.69B-12.75B-39.80B-38.05B-1.65B-29.58B
Investing Cash Flow-28.17B-3.24B-2.45B-26.93B-54.82B-53.65B17.77B-185.62B1.64B-64.39B-7.70B-1.92B-34.28B-11.22B-
Financing Cash Flow30.06B8.24B7.53B25.76B20.41B81.10B-3.64B250.93B3.33B73.36B43.09B31.63B60.43B7.96B-
Capital Expenditure1.03B7.90B5.68B2.42B20.29B5.07B20.51B8.01B3.96B22.21B56.43B31.75B7.38B7.30B14.76B
Free Cash Flow----------46.81B-69.75B-71.58B-45.43B-8.95B-44.34B
FCF to OCF---------206.28%547.28%179.85%119.39%543.03%149.89%

Earnings

Report DateSep 30, 2009Dec 31, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Aug 12, 2014Nov 13, 2014Mar 3, 2015May 16, 2015Aug 11, 2015Nov 13, 2015Jan 27, 2016May 13, 2016Aug 12, 2016Nov 14, 2016Feb 8, 2017May 15, 2017Aug 15, 2017Nov 14, 2017Feb 28, 2018May 15, 2018Aug 14, 2018Nov 14, 2018Feb 20, 2019May 13, 2019Aug 13, 2019Nov 14, 2019Mar 4, 2020May 15, 2020Aug 13, 2020Nov 4, 2020Mar 11, 2021Jun 22, 2021Aug 17, 2021Nov 15, 2021Mar 17, 2022May 16, 2022Aug 16, 2022Nov 14, 2022Feb 10, 2023May 15, 2023Aug 14, 2023Nov 14, 2023Mar 28, 2024May 14, 2024Aug 13, 2024Nov 12, 2024Mar 13, 2025May 12, 2025Aug 29, 2025Nov 14, 2025Mar 18, 2026May 18, 2026Aug 18, 2026
EPS Estimate---------------------------------42.00-201.00-109.36-472.15-536.62-387.80-129.06-413.18-361.22-272.59-99.28------178.39-149.39-986.97489.49-466.29-382.89-226.98229.00---------
EPS Actual-44.90-13.89-27.846.864.31-149.8637.93-87.0531.42-29.82-81.36-89.09-97.14-98.87-233.1318.68-66.29-114.23-169.8323.1956.09-453.02247.61-200.37-311.73-249.58-269.60-305.40-269.70149.84-278.01-553.36-223.00-808.00-91.00981.54-802.31-429.00-678.80-222.31-288.46-214.61-299.96861.35-806.74-651.92-1303.83474.99-439.46-574.62-1539.00-665.00-603.00-504.0076.00-279.03-291.69-350.80-589.45-416.10-323.29462.89-321.91-273.62-577.57
Surprise---------------------------------430.95%-301.99%16.79%307.89%-49.51%-10.62%-425.96%46.20%20.14%21.27%-202.14%------146.35%-284.64%-55.93%-235.86%-29.32%-31.63%133.48%-221.85%---------
Timing----------------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hours-----

Key Statistics & Ratios

Market Cap127.34B
Enterprise Value213.45B
Trailing P/E0.00
Forward P/E0.00
Price / Sales21.93
Price / Book0.62
Revenue (TTM)5.81B
Gross Profit (TTM)-196.75M
EBITDA-38.14B
Profit Margin0.00%
Operating Margin-609.89%
Return on Equity-17.31%
Return on Assets-6.70%
Shares Outstanding45.48M
Shares Float33.87M
Beta0.41
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jan 11, 202313:10
  • Nov 9, 2022939:877
  • Mar 2, 20162:1